What is it about?

The CompLEEment-1 trial explores a treatment for advanced breast cancer (ABC) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) tumors. It's one of the largest studies investigating cyclin-dependent kinase 4 and 6 inhibitors for this type of cancer. The trial tests the safety and effectiveness of ribociclib, letrozole, and goserelin/leuprolide combination therapy. [Some of the content on this page has been created by AI]

Featured Image

Why is it important?

Breast cancer is a significant health concern, and finding effective treatments is crucial. This study investigates a promising combination therapy for advanced breast cancer, aiming to improve patient outcomes and quality of life. By assessing safety, tolerability, efficacy, and quality of life, researchers aim to provide valuable insights into a potential frontline treatment option for HR+, HER2– advanced breast cancer. Key Takeaways: 1. The study explores a combination therapy for advanced breast cancer involving ribociclib, letrozole, and goserelin/leuprolide. 2. Safety and tolerability of the treatment were assessed, with a focus on managing adverse events. 3. Efficacy results show promising median time to progression, indicating potential benefits for patients. 4. Quality of life for patients was maintained during the treatment period, suggesting overall well-being was not compromised. 5. These findings support the use of ribociclib plus letrozole as a first-line treatment option for patients with HR+, HER2– advanced breast cancer, based on consistent safety and efficacy data from previous trials.

Read the Original

This page is a summary of: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population, Breast Cancer Research and Treatment, August 2021, Springer Science + Business Media,
DOI: 10.1007/s10549-021-06334-0.
You can read the full text:



Be the first to contribute to this page